All Stories

  1. Hepatitis B virus infection in post-vaccination South Africa: Occult HBV infection and circulating surface gene variants
  2. Characterization of HCV Genotype 5a Envelope Proteins: Implications for Vaccine Development and Therapeutic Entry Target
  3. Prediction of T-cell epitopes of hepatitis C virus genotype 5a
  4. Mutations associated with occult hepatitis B in HIV‐positive South Africans
  5. Active co‐infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy
  6. Sustained favourable HIV viral load response in South African patients during concomitant HAART and cancer therapy
  7. High levels of susceptibility and active hepatitis B infection in Gauteng healthcare workers
  8. Human cytomegalovirus gB genotype distribution among HIV infected patients from Pretoria
  9. Prediction of immunological T-cell epitopes of hepatitis C virus genotype 5a
  10. Evidence for shifting hepatitis B virus population epidemiology after nearly two decades of universal hepatitis B vaccination in South Africa
  11. Frequent Detection of HBV and HCV infection in HIV positive cancer patients undergoing chemotherapy or radiotherapy at Dr George Mukhari Academic hospital, Pretoria, South Africa
  12. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa
  13. Near full-length genome analysis of HCV genotype 5 strains from South Africa
  14. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa
  15. Genetic Characterization of HIV Before Widespread Testing of HIV Vaccine Candidates at a Clinical Trial Site in Pretoria, South Africa
  16. Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa
  17. Prevalence of Antiretroviral Drug Resistance Mutations and HIV-1 Subtypes among Newly-diagnosed Drugnaïve Persons Visiting A Voluntary Testing and Counselling Centre in Northeastern South Africa
  18. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes
  19. Increased detection of HBV DNA in HBsAg‐positive and HBsAg‐negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital
  20. Mutations associated with lamivudine‐resistance in therapy‐naïve hepatitis B virus (HBV) infected patients with and without HIV co‐infection: Implications for antiretroviral therapy in HBV and HIV co‐infected South African patients